TITLE

Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients

AUTHOR(S)
Tiffany Ng Shi Yeen; Pathmanathan, Rajadurai; Shiran, Mohd Sidik; Ahmad Zaid, Fattah Azman; Cheah, Yoke Kqueen
PUB. DATE
June 2013
SOURCE
Journal of Biomedical Science;2013, Vol. 20 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Somatic mutations of the epidermal growth factor receptor (EGFR) are reportedly associated with various responses in non-small cell lung cancer (NSCLC) patients receiving the anti-EGFR agents. Detection of the mutation therefore plays an important role in therapeutic decision making. The aim of this study was to detect EGFR mutations in formalin fixed paraffin embedded (FFPE) samples using both Scorpion ARMS and high resolution melt (HRM) assay, and to compare the sensitivity of these methods. Results: All of the mutations were found in adenocarcinoma, except one that was in squamous cell carcinoma. The mutation rate was 45.7% (221/484). Complex mutations were also observed, wherein 8 tumours carried 2 mutations and 1 tumour carried 3 mutations. Conclusions: Both methods detected EGFR mutations in FFPE samples. HRM assays gave more EGFR positive results compared to Scorpion ARMS.
ACCESSION #
88014051

 

Related Articles

  • Clinicopathological and immunohistochemical profile of non- small cell lung carcinoma in a tertiary care medical centre in South India. Shankar, Shanmugapriya; Thanasekaran, Vijayalakshmi; Dhanasekar, T.; Duvooru, Prathiba // Lung India;Jan-Mar2014, Vol. 31 Issue 1, p23 

    Background: Lung cancer is a highly aggressive malignancy causing high morbidity and mortality. An increasing incidence of lung cancer has been observed in India. Currently, the classification of lung carcinoma has gone beyond small cell lung carcinoma and non-small cell lung carcinoma (NSCLC)....

  • Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. Abdelraouf, Fatma; Sharp, Adam; Maurya, Manisha; Mair, Debbie; Wotherspoon, Andrew; Leary, Alex; Gonzalez de Castro, David; Bhosle, Jaishree; Nassef, Ayatallah; Gaafar, Taghrid; Popat, Sanjay; Yap, Timothy A.; O'Brien, Mary // BMC Research Notes;11/18/2015, Vol. 8, p1 

    Background: There is an urgent need to identify molecular signatures in small cell lung cancer (SCLC) that may select patients who are likely to respond to molecularly targeted therapies. In this study, we investigate the feasibility of undertaking focused molecular analyses on routine...

  • Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial†. Zhou, Q.; Cheng, Y.; Yang, J.-J.; Zhao, M.-F.; Zhang, L.; Zhang, X.-C.; Chen, Z.-H.; Yan, H.-H.; Song, Y.; Chen, J.-H.; Feng, W.-N.; Xu, C.-R.; Wang, Z.; Chen, H.-J.; Zhong, W.-Z.; Liu, Y.-P.; Wu, Y.-L. // Annals of Oncology;Dec2014, Vol. 25 Issue 12, p2385 

    CTONG0806, a multicenter phase II randomized trial, is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment for EGFR wild-type advanced non-squamous NSCLC. ARMS should be recommended as standard...

  • Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Hattar, Katja; Savai, Rajkumar; Subtil, Florentine; Wilhelm, Jochen; Schmall, Anja; Lang, Dagmar; Goldmann, Torsten; Eul, Bastian; Dahlem, Gabriele; Fink, Ludger; Schermuly, Ralph-Theo; Banat, Gamal-Andre; Sibelius, Ulf; Grimminger, Friedrich; Vollmer, Ekkehard; Seeger, Werner; Grandel, Ulrich // Cancer Immunology, Immunotherapy;Feb2013, Vol. 62 Issue 2, p309 

    Lung cancer is frequently complicated by pulmonary infections which may impair prognosis of this disease. Therefore, we investigated the effect of bacterial lipopolysaccharides (LPS) on tumor proliferation in vitro in the non-small cell lung cancer (NSCLC) cell line A549, ex vivo in a tissue...

  • Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Lee, Chee Khoon; Brown, Chris; Gralla, Richard J.; Hirsh, Vera; Thongprasert, Sumitra; Tsai, Chun-Ming; Tan, Eng Huat; Ho, James Chung-Man; Chu, Da Tong; Zaatar, Adel; Osorio Sanchez, Jemela Anne; Vu, Vu Van; Au, Joseph Siu Kie; Inoue, Akira; Lee, Siow Ming; Gebski, Val; Yang, James Chih-Hsin // JNCI: Journal of the National Cancer Institute;5/1/2013, Vol. 105 Issue 9, p595 

    Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for regulating tumorigenesis and cell survival and may be important in the development and progression of non–small cell lung cancer (NSCLC). We examined the impact of EGFR–tyrosine kinase...

  • CORRIGENDA.  // Current Oncology;Jun2012, Vol. 19 Issue 3, pe228 

    A correction to the article "A personalized approach to treatment: Use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada" that was published in the 2012 issue is presented.

  • Loss of Bad expression confers poor prognosis in non-small cell lung cancer. Huang, Yi; Liu, Dan; Chen, Bojiang; Zeng, Jing; Wang, Lei; Zhang, Shangfu; Mo, Xianming; Li, Weimin // Medical Oncology;Sep2012, Vol. 29 Issue 3, p1648 

    Proapoptotic BH-3-only protein Bad (Bcl-Xl/Bcl-2-associated death promoter homolog, Bad) initiates apoptosis in human cells, and contributes to tumorigenesis and chemotherapy resistant in malignancies. This study explored association between the Bad expression level and prognosis in patients...

  • Mixed Anaplastic Small-Cell and Squamous-Cell Carcinoma of the Lung. Brereton, Harmar D.; Mathews, Mary M.; Costa, Jose; Kent, Harry; Johnson, Ralph E. // Annals of Internal Medicine;Jun78, Vol. 88 Issue 6, p805 

    Discusses the association of small-cell anaplastic and squamous-cell lung cancer in an autopsy series. Description of patients examined; Barries to the demonstration of squamous- and small-cell elements within the same tumor.

  • Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China. Lan-Ying Gou; Yi-Long Wu // Lung Cancer: Targets & Therapy;2014, Vol. 5, p1 

    Lung cancer is a leading cause of cancer-related mortality worldwide and in the People's Republic of China. Recently, the pathological proportions of the various forms of lung cancer have changed. A shift to a preponderance of adenocarcinoma at the expense of squamous cell carcinoma is...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics